According to the Waltham, MA-based contract research organization (CRO), the medical writing solutions team is made up of more than 800 experts around the globe.
“We have seen the drug development journey continue to evolve, with advancements in trial design and technology, changing regulatory requirements, and the growing need to communicate effectively to a multi-faceted audience, including investigators, patients, agencies, and authorities,” said Julia Cooper, vice president, head of global medical writing solutions at Parexel.
“As a result, biopharmaceutical companies must have access to highly-experienced medical writers who can communicate with all stakeholders in an integrated way through each critical stage of development and commercialization,” she told us.
Cooper explained the new offering will ensure an integrated and streamlined communications strategy across the drug development and commercialization continuum.
“In order to meet product development and commercialization demands, biopharmaceutical companies are increasingly being held to a higher standard of quality documentation,” she added.
Earlier this month, Parexel announced the appointment of its new CEO, Jamie Macdonald. The company also recently partnered with BioFortis to offer biological sample lifecycle management services.